Rontalizumab (DrugBank: Rontalizumab)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-121864 | 01/6/2012 | A Phase I study of rontalizumab | A Phase I study of rontalizumab | Systemic lupus erythematosus (SLE) | Intervention name : Rontalizumab Dosage And administration of the intervention : Single and multiple subcutaneous administration of 3 different doses of rontalizumab Control intervention name : null | Chugai Pharmaceutical Co., Ltd. | NULL | 20 | 64 | BOTH | 21 | Phase 1 | NULL | ||
| 2 | NCT00962832 (ClinicalTrials.gov) | September 2009 | 19/8/2009 | A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Placebo;Drug: Rontalizumab | Genentech, Inc. | NULL | Completed | 18 Years | 65 Years | Both | 238 | Phase 2 | United States;Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom |